The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events. by Wandeler, G. et al.
CLINICAL SCIENCE
The J-Curve in HIV: Low and Moderate Alcohol Intake
Predicts Mortality but Not the Occurrence of Major
Cardiovascular Events
Gilles Wandeler, MD, MSc,*† David Kraus, PhD,*† Jan Fehr, MD,‡ Anna Conen, MD,§
Alexandra Calmy, MD,k Christina Orasch, MD,¶ Manuel Battegay, MD,# Patrick Schmid, MD,**
Enos Bernasconi, MD,†† and Hansjakob Furrer, MD,* the Swiss HIV Cohort Study
Objectives: In HIV-negative populations, light-to-moderate alco-
hol consumption is associated with a lower cardiovascular morbidity
and mortality than alcohol abstention. Whether the same holds true
for HIV-infected individuals has not been evaluated in detail.
Design: Cohort study.
Methods: Adults on antiretroviral therapy in the Swiss HIV Cohort
Study with follow-up after August 2005 were included. We catego-
rized alcohol consumption into: abstention or very low (,1 g/d), low
(1–9 g/d), moderate (10–29 g/d in women and 10–39 g/d in men), and
high alcohol intake. Cox proportional hazards models were used to
describe the association between alcohol consumption and cardiovas-
cular disease-free survival (combined endpoint), cardiovascular
disease events (CADE) and overall survival. Baseline and
time-updated risk factors for CADE were included in the models.
Results: Among 9741 individuals included, there were 788 events
of major CADE or death during 46,719 patient-years of follow-up,
corresponding to an incidence of 1.69 events/100 person-years.
Follow-up according to alcohol consumption level was 51% no or
very low, 20% low, 23% moderate, and 6% high intake. As
compared with no or very low alcohol intake, low (hazard ratio
0.79, 95% conﬁdence interval 0.63 to 0.98) and moderate alcohol
intakes (0.78, 0.64 to 0.95) were associated with a lower incidence of
the combined endpoint. There was no signiﬁcant association
between alcohol consumption and CADE.
Conclusions: Compared with no or very low alcohol consumption,
low and moderate intake associated with a better CADE-free
survival. However, this result was mainly driven by mortality and
the speciﬁc impact of drinking patterns and type of alcoholic
beverage on this outcome remains to be determined.
Key Words: alcohol consumption, HIV infection, mortality, car-
diovascular diseases, cohort study
(J Acquir Immune Deﬁc Syndr 2016;71:302–309)
INTRODUCTION
In the general population, episodic intake of large
amounts of alcohol increases mortality,1 whereas low-to-
moderate alcohol consumption is associated with a lower
cardiovascular morbidity and mortality compared with alco-
hol abstention.2,3 Whether the latter association depends on
the type of alcoholic beverage, the frequency of intake or on
associated socio-cultural behaviors remains of debate.2,4,5
In HIV-infected individuals, excessive alcohol con-
sumption has been associated with several negative outcomes,
including mortality, increased sexual risk behavior, lower
adherence to and higher interruptions of antiretroviral therapy
(ART), and impaired response to ART.6–9 However, only
a few studies have assessed the impact of alcohol consumption
on cardiovascular outcomes in this population. Low or
moderate alcohol consumption was associated with a low
prevalence of cardiovascular disease in an American cross-
sectional study10 and a reduced risk of major cardiovascular
disease events (CADE) in a prospective multisite French
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cohort.11 Although the ﬁrst study did not differentiate between
no alcohol intake and low or moderate consumption, the
second was limited by a small sample size and a low number
of observed cardiovascular events. Importantly, neither study
assessed the impact of low and moderate alcohol consumption
on CADE-free survival and overall mortality.
We performed a thorough analysis of the association
between different levels of alcohol consumption and CADE-
free survival and overall mortality in a large, nationwide HIV
cohort. To reduce confounding, time-updated data on the
quantity and patterns of alcohol consumption and detailed
information on all important cardiovascular risk factors and
HIV-related clinical parameters were adjusted for.
METHODS
The Swiss HIV Cohort Study
The Swiss HIV Cohort Study (SHCS, www.shcs.ch) is
a prospective cohort study with ongoing enrollment of HIV-
infected adults in Switzerland since 1988. It covers close to
50% of the cumulative number of HIV infections declared to
the Swiss public health authorities and 75% of individuals
receiving ART in Switzerland.12 Representativeness remained
stable over the years. Detailed information on demographics,
mode of HIV acquisition, risk behavior, clinical events,
coinfections, comorbidities, and treatment is collected using
a standard protocol at registration and then at intervals of 6
months. Local ethical committees of all participating study
sites have approved the study and written consent has been
obtained from all participants.
Inclusion Criteria and Definitions
We included all adult individuals enrolled in the SHCS,
who started ART and had at least 1 follow-up visit with
available information on alcohol consumption. We considered
individual follow-up starting at the ﬁrst visit with available
alcohol data. The alcohol questionnaire was introduced into the
SHCS routine questionnaire in August 2005. Since then, data
on self-reported alcohol consumption were collected at 6
months intervals for every patient. The questionnaire captures
information on the frequency, quantity, and pattern of alcohol
consumption. For this analysis, self-reported alcohol consump-
tion was categorized into: abstention or very low (,1 g/d), low
(1–9 g/d), moderate (10–29 g/d in women and 10–39 g/d in
men), and high alcohol intake (.39 g/d).
Outcomes
Our primary outcome was a combined endpoint of
either death or CADE (CADE-free survival), whichever
occurred ﬁrst. CADE included myocardial infarction, coro-
nary angioplasty, coronary artery bypass grafting, carotid
endarterectomy, procedures on other arteries, cerebral infarc-
tion, and cerebral hemorrhage. In the SHCS, data on all
cardiovascular events are collected on speciﬁc, standardized,
case-report forms, using reports from medical hospitalizations
and performed surgery to inform and validate the diagnosis.
The secondary endpoints were the separate outcomes:
CADE, overall survival, and cardiovascular death.
Statistical Analyses
Baseline characteristics of patients at study inclusion
were compared between baseline alcohol consumption levels
using Kruskal–Wallis and x2 tests for continuous and
categorical variables, respectively. The distribution of clinical
outcomes across categories of alcohol intake was presented as
absolute numbers and proportions.
Cox proportional hazards models were used to evaluate
the association between time-updated alcohol consumption
level and CADE-free survival (combined endpoint) and CADE
and overall survival. Follow-up was censored at the time of ﬁrst
major CADE, death, or last recorded visit, whichever occurred
ﬁrst. These models were adjusted for all relevant baseline
demographic and clinical characteristics, including sex, ethnic-
ity (black vs. others), education level [low (no or basic
education), intermediate (high school), and high (high-level
education)], HIV transmission group (heterosexual, men who
have sex with men, injection drug users, and others), hepatitis C
infection (presence of positive hepatitis C virus RNA), hepatitis
B infection (positive hepatitis B surface antigen), center for
diseases control stage of infection, and family history of
cardiovascular disease (yes/no). Anemia, an important predictor
of mortality among HIV-infected patients,13 was included as
a binary, time-updated variable (yes/no, cutoff value for women
12 g/dL and for men 14 g/dL) as the prevalence of severe
anemia was inferior to 1% in our cohort. Age, body mass index
(normal, underweight, or overweight/obese), smoking (packs
per day), random cholesterol levels [total cholesterol/high-
density lipoprotein (HDL)-cholesterol ratio], diabetes mellitus
(yes/no), arterial hypertension (yes, if systolic blood pressure
exceeds 140 mm Hg or diastolic blood pressure exceeds 90 mm
Hg; no otherwise), CD4 cell count, log HIV viral load, and
ART regimens [cumulative exposure to abacavir (ABC),
efavirenz, nevirapine, and protease inhibitors] were included
as time-varying covariates. We carried forward the last observed
value of time-dependent covariates. To describe the overall
cardiovascular risk proﬁle of the different comparison groups,
we used the Framingham 10-year cardiovascular disease risk
score as a summary measure.14 The association between alcohol
consumption and CADE-free survival was shown in ﬁgures
including alcohol as a continuous and categorical variable.
Similar ﬁgures were reproduced for the associations between
alcohol intake and the secondary outcomes.
Sensitivity Analyses
Education level is associated with health seeking
behavior and could condition drinking patterns. Thus, to
assess the possible link between education level and CADE-
free survival, we repeated our analyses after stratiﬁcation by
education level categories and a formal test of interaction was
performed. Furthermore, to evaluate the impact of the
deﬁnition of our main independent variable, self-reported
alcohol consumption, on the primary outcome, we compared
the results of the main analysis with those of a sensitivity
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analysis in which current alcohol intake was replaced by time-
updated average consumption since the beginning of the
follow-up period. Finally, “sick quitters” could have been
included into the “no/very low alcohol consumption group”
and inﬂuenced our results. Thus, we repeated the main
analyses after excluding the patients with an aspartate
aminotransferase-to-Platelet Ratio Index (APRI) score corre-
sponding to liver cirrhosis (APRI .2.0) from this alcohol use
category. All statistical analyses were performed using R
Version 2.15.2.
RESULTS
Baseline Characteristics
Of 9764 patients included in the study, 51% reported no
or very low alcohol consumption at baseline, whereas 20%,
22%, and 7% had a low, moderate, and high alcohol intake,
respectively (Table 1). Individuals with no or very low
alcohol intake were more likely to be woman and of black
ethnicity. The groups with low or moderate alcohol con-
sumption at baseline had the lowest proportions of injection
drug users and the highest proportion of highly educated
patients. Cardiovascular disease risk proﬁle differed between
groups. Framingham cardiovascular disease 10-year risk
score increased with alcohol intake at baseline, reaching
7.3% in the group with high alcohol consumption. Whereas
smoking and arterial hypertension were most prevalent in this
group, participants with no or very low alcohol intake were
most likely to have diabetes mellitus and anemia.
Individual drinking habits remained fairly constant over
time: 53% of patients spent at least 80% of their follow-up
time in the same drinking category and 92% spent at least
50% of their time in 1 category. The incidence rate of change
of alcohol consumption category was 0.44 per person-year
(py) of follow-up.
Distribution of CADE and Death According to
Alcohol Intake
During 46,719 patient-years of follow-up, 788 individ-
uals either developed a CADE or died; there were 343 CADE
TABLE 1. Baseline Characteristics of Study Population by Level of Alcohol Intake
No or Very Low N = 5006 Low N = 1950 Moderate N = 2170 High N = 638 P
Female sex (%) 1970 (39.4) 442 (22.7) 343 (15.8) 135 (21.2) ,0.001
Median age (IQR), yrs 41 (34–47) 41 (36–48) 43 (37–49) 44 (39–50) ,0.001
Black ethnicity (%) 956 (19.1) 178 (9.1) 183 (8.4) 32 (5.0) ,0.001
HIV transmission group (%) ,0.001
Heterosexual 2232 (46.6) 628 (32.2) 686 (31.6) 233 (36.5)
IDU 911 (18.2) 195 (10.0) 288 (13.3) 180 (28.2)
MSM 1589 (31.7) 1053 (54.0) 1116 (51.4) 209 (32.8)
Other 274 (5.5) 74 (3.8) 80 (3.7) 16 (2.5)
Education level (%) ,0.001
No 1524 (31.7) 329 (17.4) 427 (20.2) 176 (29.1)
Basic 2278 (47.4) 1029 (54.3) 1032 (48.9) 312 (51.7)
High level 1003 (20.9) 537 (28.3) 651 (30.9) 116 (19.2)
Median CD4 count (IQR) 379 (247–570) 380 (260–560) 392 (264–85) 360 (231–550) 0.01
Median log HIV RNA (IQR) 0 (0–4) 1.7 (0–4.5) 1.5 (0–4.5) 1.9 (0–4.4) ,0.001
HCV infection (%) 253 (5.1) 84 (4.3) 74 (3.4) 35 (5.5) 0.01
HBV infection (%) 261 (5.2) 72 (3.7) 105 (4.8) 33 (5.2) 0.06
CDC stage C (%) 1277 (25.5) 384 (19.7) 455 (21.0) 148 (23.2) ,0.001
PI-based ART (%) 2559 (51.1) 1020 (52.3) 948 (43.7) 288 (45.1) ,0.001
ART including ABC (%) 949 (19.0) 352 (18.1) 439 (20.2) 101 (15.8) 0.06
Family history (%) 513 (10.5) 215 (11.3) 271 (12.7) 69 (11.1) 0.07
Total cholesterol/HDL-cholesterol ratio 4.0 (3.2–5.1) 4.0 (3.1–5.0) 4.0 (3.2–5.0) 3.6 (2.8–4.5) ,0.001
Median HDL-cholesterol (IQR), mmol/L 1.1 (0.9–1.4) 1.1 (0.9–1.4) 1.2 (0.9–1.5) 1.3 (1.0–1.7) ,0.001
Diabetes (%) 185 (3.7) 58 (3.0) 44 (2.0) 13 (2.0) 0.001
BMI (%) ,0.001
Normal 2997 (62.3) 1225 (64.3) 1383 (66.3) 425 (68.4)
Underweight 389 (8.1) 105 (5.5) 100 (4.8) 44 (7.1)
Overweight/obese 1423 (29.6) 575 (30.2) 604 (28.9) 152 (24.5)
Arterial hypertension (%) 766 (15.4) 381 (19.6) 398 (18.5) 170 (26.6) ,0.001
Median pack/d smoking (IQR) 0 (0–0.8) 0 (0–0.8) 0 (0–1) 1.0 (0–1.2) ,0.001
Anemia (%) 1863 (37.2) 599 (30.7) 664 (30.6) 208 (32.6) ,0.001
Median Framingham score (IQR) 4.5 (2.0–9.4) 5.2 (2.6–10.2) 6.5 (3.3–11.9) 7.3 (3.9–12.8) ,0.001
BMI, body mass index; CDC, center for diseases control; HBV, hepatitis B virus; HCV, hepatitis C virus; IDU, injection drug users; IQR, interquartile range; MSM, men who have
sex with men; PI, protease inhibitor.
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and 491 deaths (Table 2). Heart CADE, including myocardial
infarction, coronary angioplasty, and coronary artery bypass
graft were observed in 199 patients (58% of all CADE). The
combined outcome was observed in 442 (8.8%) patients with
no or very low alcohol consumption at baseline, whereas 118
(6.1%), 155 (7.1%), and 73 (11.4%) patients with low,
moderate, and high alcohol intake developed a CADE or
died, respectively. In total, 12.6% of all deaths (62/491) were
due to cardiovascular events.
Incidence of CADE or Death
The incidence of CADE or death (whichever occurred
ﬁrst) was 1.69 events/100 py [95% conﬁdence interval (CI)
1.57 to 1.81]. Overall follow-up time was distributed as
follows according to time-updated alcohol consumption: no
or very low: 50.6%, low: 20.4%, moderate: 23.3%, and high:
5.7%. Compared with no or very low alcohol intake, low
[hazard ratio (HR) 0.79, 95% CI: 0.63 to 0.98] and moderate
alcohol intake (0.78, 0.64 to 0.95) were associated with
a lower incidence of the combined endpoint, whereas no
association was detected for high intake (1.02, 0.78 to 1.34)
(Table 3). Figure 1 shows a ﬁtted curve of the association
between daily alcohol consumption category or continuous
level with the HR of the combined endpoint. The classical
cardiovascular risk factors, including age, diabetes mellitus,
smoking, total cholesterol/HDL-cholesterol ratio and arterial
hypertension, and low CD4 cell count and anemia were
signiﬁcantly associated with a higher hazard of CADE or
death. A strong association between education level and the
combined outcome was also observed (high vs. low: HR 0.73,
95% CI: 0.59 to 0.95). Finally, a signiﬁcant association
between cumulative treatment with ABC and protease
inhibitors and CADE or death could also be shown.
Secondary Outcomes
The level of alcohol intake predicted overall survival.
We observed 491 deaths during 48,000 py of follow-up,
which corresponds to an incidence of 1.03/100 py (95% CI:
0.94 to 1.12). A J-curve similar to the one for the combined
outcome could be shown (Fig. 2). Compared with very low
alcohol consumption, low (HR 0.57, 95% CI: 0.42 to 0.78)
and moderate alcohol intake (0.60, 0.46 to 0.80) were
associated with a lower incidence of death. Again, there
was no association between high alcohol intake and death
(HR 1.02, 0.74 to 1.42). Education level and all classical
cardiovascular risk factors were associated with mortality,
whereas no speciﬁc antiretroviral drug was associated with
this outcome. During 47,000 py of follow-up, 343 CADE
were noted, which corresponded to an incidence of 0.73/100
py (95% CI: 0.66 to 0.82). However, low (HR 1.09, 95% CI:
0.81 to 1.47) or moderate (1.02, 0.77 to 1.35) alcohol
consumption were not associated with a lower hazard of
CADE, as shown in Figure 2. Similarly, low (HR 1.05, 95%
CI: 0.50 to 2.22) or moderate (HR 1.03, 95% CI: 0.51 to 2.05)
alcohol consumption did not seem to be associated with lower
hazard for cardiovascular death.
Sensitivity Analyses
In stratiﬁed analyses, the J-shaped curve of the
association between low/moderate alcohol intake and the
combined outcome remained statistically signiﬁcant for
the groups of participants with low or intermediate educa-
tion levels (see Figure S1, Supplemental Digital Content,
http://links.lww.com/QAI/A757). This was not the case for
high education level, but the number of patients in this
category reporting high alcohol consumption was low.
There was no evidence of an interaction between alcohol
consumption and education levels in their association with
CADE or death (P = 0.64). Replacing time-updated alcohol
consumption by average intake as the main independent variable
did not change the association between low/moderate alcohol
intake and the combined outcome (see Figure S2, Supplemental
Digital Content, http://links.lww.com/QAI/A757). Finally, the
results of the main analyses obtained after the exclusion of
potential sick quitters did not vary signiﬁcantly from the original
results (data not shown).
DISCUSSION
Compared with abstention or very low consumption,
low and moderate alcohol intakes were associated with
a better CADE-free survival and overall survival in partic-
ipants of the SHCS receiving ART. These observations
persisted after adjustment for a wide range of classical
baseline and time-updated cardiovascular risk factors and
other known predictors of mortality such as CD4 cell count
and anemia. However, the incidence of CADE seemed to be
lower with increasing alcohol consumption, possibly because
of competing risks. The J-shaped association between alcohol
consumption and mortality shown previously in the general
population also seems to hold true in HIV-infected individ-
uals on ART.
TABLE 2. Distribution of Outcomes by Level of Alcohol Intake
No or Very
Low Low Moderate High
No. patients 5006 1950 2170 638
Myocardial infarction (%) 53 (1.1) 29 (1.5) 37 (1.7) 7 (1.1)
Coronary angioplasty (%) 29 (0.6) 11 (0.6) 18 (0.8) 4 (0.6)
Coronary artery bypass
graft (%)
6 (0.1) 3 (0.2) 1 (0.1) 1 (0.2)
Carotid
endarterectomy (%)
2 (0.04) 1 (0.1) 0 1 (0.2)
Procedures on other
arteries (%)
28 (0.6) 7 (0.4) 11 (0.5) 2 (0.3)
Cerebral infarction (%) 39 (0.8) 16 (0.8) 17 (0.8) 6 (0.9)
Cerebral hemorrhage (%) 4 (0.1) 2 (0.1) 6 (0.3) 2 (0.3)
Deaths (%) 313 (6.3) 53 (2.7) 71 (3.3) 54 (8.4)
CV deaths 27 (0.5) 10 (0.5) 14 (0.6) 11 (1.7)
Combined outcomes
CADE (%) 161 (3.2) 68 (3.5) 90 (4.1) 23 (3.6)
Heart CADE (%) 88 (1.8) 43 (2.2) 56 (2.6) 12 (1.9)
CADE or death (%) 442 (8.8) 118 (6.1) 155 (7.1) 73 (11.4)
CADE or CV death (%) 178 (3.6) 76 (3.9) 102 (4.7) 31 (4.9)
CADE, cardiovascular disease event; CV, cardiovascular.
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TABLE 3. Predictors of CADE or Death
Univariable Analysis Multivariable Analysis
HR (95% CI) P HR (95% CI) P
Alcohol intake ,0.001 0.03
No or very low Ref. Ref.
Low 0.66 (0.54 to 0.81) 0.79 (0.63 to 0.98)
Moderate 0.76 (0.64 to 0.92) 0.78 (0.64 to 0.95)
High 1.45 (1.13 to 1.86) 1.02 (0.78 to 1.34)
Sex ,0.001 0.39
Male Ref. Ref.
Female 0.62 (0.53 to 0.74) 0.91 (0.74 to 1.12)
Median age in years ,0.001 ,0.001
Per 1 yr increase 1.06 (1.06 to 1.07) 1.06 (1.05 to 1.07)
Education level 0.10 0.03
No/basic Ref. Ref.
High school 0.97 (0.82 to 1.15) 0.82 (0.68 to 0.98)
High level 0.81 (0.65 to 1.00) 0.75 (0.59 to 0.95)
Transmission group ,0.001 ,0.001
HET Ref. Ref.
IDU 2.27 (1.91 to 2.70) 1.71 (1.37 to 2.12)
MSM 1.09 (0.92 to 1.29) 1.00 (0.82 to 1.22)
Ethnicity ,0.001 0.01
Nonblack Ref. Ref.
Black 0.27 (0.19 to 0.38) 0.55 (0.37 to 0.83)
Anemia ,0.001 ,0.001
No Ref. Ref.
Yes 3.51 (3.05 to 4.04) 2.36 (2.02 to 2.77)
Log CD4 count ,0.001 ,0.001
Per 1 log increase 0.15 (0.13 to 0.18) 0.26 (0.21 to 0.32)
CDC stage C ,0.001 0.01
No Ref. Ref.
Yes 2.02 (1.75 to 2.32) 1.22 (1.04 to 1.43)
Log HIV RNA ,0.001 0.08
Per 1 log increase 1.17 (1.12 to 1.23) 1.05 (0.99 to 1.11)
HBV exposure 0.19 0.17
No Ref. Ref.
Yes 1.22 (0.91 to 1.65) 1.25 (0.91 to 1.72)
HCV infection 0.03 0.13
No Ref. Ref.
Yes 1.38 (1.04 to 1.83) 0.78 (0.56 to 1.08)
Cumulative ABC exposure ,0.001 ,0.001
Per unit increase 1.09 (1.06 to 1.11) 1.08 (1.05 to 1.10)
Cumulative EFV exposure 0.38 0.53
Per unit increase 1.01 (0.99 to 1.04) 1.01 (0.98 to 1.04)
Cumulative NVP exposure 0.90 0.96
Per unit increase 1.00 (0.97 to 1.04) 1.00 (0.96 to 1.04)
Cumulative PI exposure ,0.001 0.09
Per unit increase 1.08 (1.06 to 1.09) 1.02 (1.00 to 1.04)
Family history 0.02 0.21
No Ref. Ref.
Yes 1.27 (1.03 to 1.55) 1.15 (0.93 to 1.43)
BMI ,0.001 ,0.001
Normal Ref. Ref.
Underweight 2.78 (2.28 to 3.39) 1.58 (1.26 to 1.97)
Overweight/obese 0.84 (071 to 0.98) 0.85 (0.71 to 1.01)
Diabetes ,0.001 ,0.001
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Of nearly 10,000 individuals included in this study,
51% were alcohol abstainers or had very low consumption at
enrollment. Similar proportions have been shown in several
studies reporting on the proportion of alcohol abstainers in
HIV-infected individuals.15,16 However, in 2 recent publica-
tions on the association between alcohol consumption and
cardiovascular events in HIV-infected individuals, American
veterans and French patients had much lower proportions of
abstainers.10,11 Estimates on low or moderate alcohol
consumption, the categories of primary interest in this study,
are not consistently reported across publications. In our
study, approximately 42% of patients were classiﬁed into
these categories at baseline and the proportion of partic-
ipants who remained in these groups over time was fairly
constant. In comparison, previous landmark studies on the
association between moderate alcohol consumption and
decreased risk of cardiovascular events in HIV-infected
and uninfected individuals had much higher proportions of
individuals with moderate alcohol intake.2,11 This is of
importance as drinking patterns often carry socio-cultural
and behavioral characteristics along, which vary widely
across settings and are themselves linked to comorbidities
and health seeking behavior.17
We found a moderate association between low or
moderate alcohol consumption and CADE-free and overall
survival, after adjustment for all relevant cardiovascular risk
factors and parameters of advanced HIV disease. The impact
of alcohol intake on these outcomes was consistent across
strata of education level and did not change signiﬁcantly
whether alcohol was considered as a time-varying covariate or
an average estimate. Furthermore, these J-shaped associations
could be shown in analyses including alcohol intake as
a categorical or continuous variable and the magnitude was
similar to published analyses from studies in HIV-uninfected
patients.18,19 These ﬁndings conﬁrm the results of larger
studies in the general population, where a causal link between
moderate alcohol consumption and mortality has become
evident, including the biological plausibility.3,20 Although
HDL-cholesterol levels increased with higher alcohol intake
in our study, there was no difference between abstainers and
patients with low alcohol intake. Thus, the potential protective
effect of HDL-cholesterol linked to the consumption of red
wine could not be shown.
In contrast to the study by Carrieri et al,11 we did not
ﬁnd a signiﬁcant association between alcohol intake and
CADE, despite having a much larger sample size and a 7-fold
higher number of major CADE, resulting in very similar
overall incidence estimates [0.73 (0.66 to 0.82) per 100
patient-years in our study vs. 0.75 (0.57 to 0.99) in Carrieri
et al11]. There are several potential explanations for these
divergent results. First, there was a large group of patients
with very low consumption in the study by Carrieri et al and
only few abstainers. Unfortunately, in our study, we were not
able to distinguish abstainers from patients with very low
alcohol consumption (less than 1 drink per week). Thus, the
category no or very low alcohol consumption could have
TABLE 3. (Continued ) Predictors of CADE or Death
Univariable Analysis Multivariable Analysis
HR (95% CI) P HR (95% CI) P
No Ref. Ref.
Yes 3.15 (2.55 to 3.91) 1.89 (1.49 to 2.40)
Arterial hypertension ,0.001 0.001
No Ref. Ref.
BMI, body mass index; CDC, center for diseases control; EFV, efavirenz; HBV, hepatitis B virus; HCV, hepatitis C virus; HET, heterosexual; IDU, injection drug users; MSM,
men who have sex with men; NVP, nevirapine; PI, protease inhibitors; Ref, reference.
FIGURE 1. Impact of daily alcohol
consumption category (A) and con-
tinuous level (B) on the combined
endpoint (CADE or death). CI, confi-
dence interval.
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included patients with good cardiovascular proﬁle (as shown
by the low Framingham cardiovascular risk score in this
group) and a smaller group of less healthy individuals (eg, sick
quitters). However, in a sensitivity analyses performed after
the exclusion of abstainers with possible liver cirrhosis, we
did not ﬁnd signiﬁcant differences in the association between
alcohol consumption and the main outcomes. Second, we
may have over corrected our model by including clinical and
laboratory CADE risk factors which may have been on
the causal pathway between alcohol consumption and
protection of CADE. However, a forward step-wise adjust-
ment strategy did not conﬁrm this potential explanation.
Finally, the difference in the results between the 2 studies
might have occurred because of the use of time-updated
covariates in our analyses.
All main cardiovascular risk factors, including age,
smoking, arterial hypertension, diabetes mellitus and hyper-
lipidemia, and anemia, were associated with the hazard of
CADE, CADE-free survival, and death. This strengthens the
validity of our model and shows the need to rely on high-
quality data on these confounders when analyzing the impact
of alcohol on long-term clinical outcomes. The impact of
several antiretroviral drugs on cardiovascular events has been
much debated in recent years. ABC has been in the forefront
of these discussions, as several large-scale observational
studies had shown its potential impact on myocardial
infarction.21,22 In our study, time spent on ABC was
a signiﬁcant risk factor of CADE and CADE-free survival
but not of overall survival. However, the point estimates were
close to 1 and we did not adjust our analyses for renal
dysfunction, which has been shown to be a potential
confounder in such analyses.22
This is the ﬁrst study to assess the impact of different
alcohol consumption levels on cardiovascular disease-free
survival in a nationwide population of HIV-infected individ-
uals. Taking advantage of the systematic and repeated
collection of detailed information on alcohol consumption
within the framework of the SHCS, we were able to
determine each patient’s intake over time and to classify all
individuals into one of the main alcohol consumption
categories. Furthermore, dedicated ascertainment of cardio-
vascular events and reasons of death and the availability of
information on all classical cardiovascular risk factors over
time allowed us to study the impact of baseline and time-
updated alcohol intake on several long-term outcomes in
detail. The main limitations of our study are the self-reported
nature of individual alcohol consumption, which might have
led to some degree of reporting bias and the lack of
information on the type of alcoholic beverage consumed.
Thus, we were not able to disentangle the relationship
FIGURE 2. Impact of daily alcohol
consumption category and continu-
ous level on separate endpoints (A
and B: death; C and D: CADE). CI,
confidence interval.
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between speciﬁc types of alcohol, for example wine in the
“French paradox,” and long-term outcomes. However, it has
been suggested that the type of alcohol might not play such an
important role as the beverage most widely consumed seems
to be the one most likely to have a protective effect on the risk
of cardiovascular events and death.5
Our study underlines the protective effect of low and
moderate alcohol consumption on cardiovascular event-free
survival and overall survival. Thus, there is no signal that
low-to-moderate alcohol consumption should be avoided by
HIV-infected persons on ART. However, the main reasons
for this association are still unclear. In this regard, the role
played by different types of alcoholic beverages, drinking
patterns, and social and behavioral characteristics linked to
them need to be further explored. Furthermore, these
ﬁndings warrant more detailed analyses of causes of death
besides cardiovascular events to inform public health
strategies and guidance on the beneﬁts and risks of low
and moderate alcohol consumption.
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